Clover Health CFO Clay Thornton told analysts on the company's August 5 earnings call that the insurer's 2027 bid had assumed continued disruption from national-carrier pullback. Its own second quarter arrived first: Medicare Advantage membership reached 157,309, up 49% year over year, while the insurance benefit expense ratio improved to 87.6% from 88.4% and GAAP net income turned to $28.0 million from an $11 million loss a year earlier (Clover Health, August 5, 2026).
The Ratio Behind the Ratio: Cohort Maturation and Expense Leverage
An 80-basis-point improvement in a benefit expense ratio sounds incremental until it is decomposed into what actually produced it. Clover's own breakdown, given on the earnings call, splits the book into two distinct cohorts with opposite economics. New members enrolled in 2026 make up 28% of current membership and are tracking in line with the company's expected early-life utilization pattern, the highest-cost phase of the relationship because a new member's chronic conditions have not yet been fully coded and their care has not yet been routed through Clover's primary-care network (Motley Fool earnings call transcript, August 12, 2026). Members who joined in 2025 are now in their second year on the plan and are producing, in management's words, "meaningfully stronger economics" than the same cohort showed a year ago, consistent with the roughly $70 per-member-per-month gross profit improvement Clover has said it expects between a cohort's first and second year.
That maturation curve is the mechanical answer to how a plan can add tens of thousands of costlier new members and still improve its aggregate ratio: the improvement in the aging book has to outrun the drag from the newest one. It worked in the second quarter. Consolidated gross profit reached $153 million, up 54% year over year, while selling, general and administrative expense fell to 15.1% of revenue for the first half of 2026 from 17.3% a year earlier, spreading a largely fixed corporate cost base across a membership base that grew nearly half again in size (Clover Health, August 5, 2026). Adjusted EBITDA for the quarter was $41 million, up 139% year over year, and cash and investments stood at $443 million with zero debt outstanding, up $53.7 million from a year earlier on operating cash flow of $133.1 million for the first half of 2026, reversing a $10.9 million outflow in the same period of 2025 (Motley Fool earnings call transcript, August 12, 2026). Full-year guidance now calls for revenue of $2.92 billion to $3.0 billion, adjusted EBITDA of $70 million to $85 million, and GAAP net income of $20 million to $35 million on average membership of 156,000 to 158,000 (Clover Health, August 5, 2026).
Three Insurers, Three Benefit-Ratio Trajectories in the Same Quarter
Clover's ratio does not exist in isolation, and the comparison across the three carriers reporting Medicare Advantage results this summer complicates any simple "upstart beats giants" reading. UnitedHealth's medical benefit ratio was 86.7% in the second quarter, an improvement from 89.4% a year earlier, still the best of the three, but the company disclosed that the result included $860 million of favorable medical reserve development, most of it tied to 2026 dates of service, a one-time-flavored tailwind rather than a repeatable expense-management gain (UnitedHealth Group, July 2026). UnitedHealth bought that ratio partly by shrinking: Medicare Advantage membership fell 965,000 since year-end 2025, and the company is guiding to a roughly 1.1 million-member decline for the full year as it exits unprofitable contracts and tightens provider networks.
Humana moved the opposite direction on the ratio while also growing. Its insurance segment benefit ratio reached 91.2% in the second quarter, worse than 89.9% a year earlier, a deterioration the company's own Form 8-K attributed to the Bonus Year 2026 Star Ratings revenue headwind, higher-cost new Medicare Advantage members, and lower prior-period reserve development (actuary.info's decomposition of the Humana filing). Individual Medicare Advantage membership at Humana grew roughly 25% year over year even as the company narrowed its county footprint to 85% of US counties for 2026 from 89% in 2025, the same prune-while-growing pattern showing up industry-wide (Kiplinger, 2026). Clover's 87.6% sits between UnitedHealth's reserve-flattered 86.7% and Humana's ratings-pressured 91.2%, produced without a comparable reserve release and without the Star Ratings drag Humana is absorbing, which is a materially different mechanism even though the three numbers cluster within five points of each other.
| Carrier | Q2 2026 Benefit Ratio | Change YoY | MA Membership Trend |
|---|---|---|---|
| UnitedHealth | 86.7% | Improved from 89.4%, aided by $860M favorable reserve development | Down 965,000 since YE2025 |
| Clover Health | 87.6% | Improved from 88.4%, driven by cohort maturation | Up 49% YoY to 157,309 |
| Humana | 91.2% | Worsened from 89.9%, driven by Star Ratings headwind and new-member mix | Individual MA up ~25% YoY |
Concentration, Not a Land Grab
The obvious read on Clover's growth, that a small insurer is expanding into counties UnitedHealth and Humana are abandoning, does not match what management described on the call. Clover's leadership said explicitly that the company does not feel compelled to expand geography for its own sake, and its membership gains are concentrated in New Jersey and Georgia, the two states where Clover has spent a decade building physician network density and where Counterpart Health, its clinical decision-support subsidiary, has the deepest data on local provider behavior (Motley Fool earnings call transcript, August 12, 2026). That is a narrower strategy than the brief version of this story suggests, and it matters for how the growth should be read actuarially: rather than opportunistically absorbing displaced members across a widening map, where underwriting information on each new member is thin, Clover is deepening penetration inside a footprint where it already has years of claims and clinical data.
Nationally, the industrywide pattern actually runs in the opposite direction from a simple giants-retreat story. Total Medicare Advantage enrollment reached 35.2 million beneficiaries in 2026, 55% of 64.2 million eligible beneficiaries, up 1.1 million, or 3%, year over year, and special needs plans accounted for 85% of that net growth (KFF, "Medicare Advantage in 2026: Enrollment Update and Key Trends"). UnitedHealth's market share fell to 26% (9.3 million enrollees) from 29%, but Humana's share rose to 20% (7 million enrollees) from 17%, a gain of 1.3 million beneficiaries, the largest absolute increase of any carrier even as Humana was simultaneously narrowing its county footprint. The two largest MA carriers together still cover 46% of the market and hold at least 75% share in 889 counties, more than a quarter of all US counties (KFF, 2026). Clover is not filling a vacuum the giants are leaving nationally; it is out-executing them inside two states it already dominates while the giants prune their weakest counties and, in Humana's case, still grow overall.
The risk-pool selection question the giants' retrenchment raises is a national one more than a Clover-specific one. When UnitedHealth exits 109 counties, affecting roughly 180,000 members, or Humana narrows availability to 85% of counties from 89%, displaced beneficiaries do not disappear; they re-enroll during the annual election period into whatever plan remains available in their county, and that re-enrollment is not risk-neutral. Beneficiaries healthy enough to actively shop tend to compare star ratings and supplemental benefits before switching, while the most complex, highest-cost members are more likely to default passively into whatever a broker or care coordinator steers them toward, or to land in a special needs plan if they qualify for dual-eligible status. A carrier that absorbs forced switchers from a giant's county exit is underwriting a population with less claims history behind it than an organically acquired member, whether or not it intentionally sought them out. Clover's growth, concentrated in New Jersey and Georgia rather than in the specific counties UnitedHealth and Humana are vacating, is less exposed to this particular selection dynamic than a carrier growing primarily by picking up displaced members in newly entered territory, which is itself part of why its 2026 cohort is tracking to expectations rather than surprising to the downside.
The Star Ratings Court Order and Its 2027 Bid Question
A separate development sits underneath Clover's 2027 margin assumptions and has nothing to do with medical cost management. Clover Insurance Company sued the Department of Health and Human Services and CMS after its largest Medicare Advantage contract received a 3.5-star rating, and a federal court ordered CMS to recalculate the rating without the disputed measures; CMS raised the contract to 4.5 stars, a change with an estimated $120 million impact on 2027 Quality Bonus Payments (Healthcare Dive, 2026). CMS subsequently moved to voluntarily recalculate 2027 Star Ratings for every Medicare Advantage organization using only the HEDIS, HOS, and CAHPS data categories authorized under federal statute, then appealed the underlying ruling to the Eleventh Circuit on July 21, 2026, meaning the 4.5-star rating Clover is bidding into for 2027 remains under active litigation.
Clover's own management is notably reluctant to lean on that number. CEO Andrew Toy told investors the rating "gives us more room to reinvest in members, maintain a highly competitive product, support growth, and expand profitability, but it does not create the economics of our model" (Fierce Healthcare, August 2026). That framing is the more conservative one for a bid actuary to take at face value: a $120 million quality bonus resting on a ruling under appeal is a favorable but reversible input, not a floor. CFO Thornton put the underlying strategy in plainer terms on the call: "We wanted to put a strong product in the market that we knew we could grow, and we knew we could grow profitably" (Motley Fool earnings call transcript, August 12, 2026), locating the 2027 bid's real support in cohort economics rather than in a bonus payment that a circuit court could still unwind.
Whether the Ratio Holds as New-Member Seasoning Continues
The actuarial question a 49% membership-growth rate raises is not whether this quarter's ratio is real, it plainly is, but whether the mix of first-year and second-year members that produced it is durable as the growth rate itself changes. A cohort now representing 28% of membership in its first, most expensive year is a smaller share of the book than it would be if Clover kept growing at 49% indefinitely; full-year guidance of 156,000 to 158,000 average members against a 157,309 second-quarter actual implies growth is decelerating into the second half, which mechanically shifts weight toward the more profitable, already-seasoned 2025 and earlier cohorts. That is favorable to the ratio holding, provided the deceleration is real and not simply a guidance range set before the quarter closed.
The reserve side of that question is the one Clover's release does not fully answer in public. The company's Q2 outperformance came from "favorable medical cost trend development," the same phrase used industry-wide to describe claims coming in lighter than reserved, which is a genuine improvement when it reflects better care management and a measurement artifact when it reflects reserves that were simply set conservatively. UnitedHealth's own $860 million of favorable Q2 development shows how large that swing factor can run even at a carrier with decades of MA claims history; a plan growing 49% a year has a thinner base of matured, fully developed claims experience on its newest cohorts to distinguish the two explanations from each other. Clover's $443 million in cash and investments and zero debt give it a real capital cushion to absorb an unfavorable reserve correction if one comes, a materially stronger position than the company held two years ago, but that cushion is also what a bid actuary should be pricing against, not assuming away, when 28% of the book has not yet completed a full claims-run-off cycle.
Rapid membership growth strains statutory capital even at a plan that is GAAP-profitable, because Medicare Advantage risk-based capital requirements are set against reserves that build immediately on enrollment, while the offsetting profit is recognized only as claims experience emerges over the following months. A plan growing 49% year over year is booking statutory reserves against a near-full year of premium on its newest cohort within weeks of enrollment, while the favorable experience that ultimately validates those reserves takes most of a plan year to fully develop. Clover's zero funded debt and $443 million cash position give it more room to fund that timing gap than it had two years ago, when the company was still absorbing GAAP losses on a smaller, less-capitalized base. But the risk-based capital math does not get easier simply because the reported ratio is improving; a carrier growing this fast has to keep raising or retaining capital roughly in step with membership even in a quarter where the income statement looks strong, which is the quieter constraint sitting behind an otherwise clean set of numbers.
Further Reading
- Humana's Q2 2026 Benefit Ratio Decomposition and Its 2027 Bid – the same quarter's ratio deterioration at the carrier gaining the most net MA membership nationally.
- 2026 MA Enrollment Surprises: SNP Growth Rewrites 2027 Bid Math – the national enrollment composition shift underneath the carrier-level numbers in this piece.
- Elevance's Star Ratings Lawsuit Against CMS – a second carrier's attempt to secure the same recalculation CMS gave Clover.
- Humana's 2027 Medicare Advantage Plan Exits and Margin Recapture – the county-pruning strategy behind Humana's benefit-ratio guidance.
- KFF's 2026 Medicare Advantage Benefits and Premiums Paradox – the broader enrollment and benefit-design backdrop this quarter's results sit inside.
Sources
- Clover Health, "Clover Health Reports Second Quarter 2026 Results," August 5, 2026
- The Motley Fool, "Clover Health (CLOV) Q2 2026 Earnings Call Transcript," August 12, 2026
- UnitedHealth Group, Q2 2026 Quarterly Report (10-Q), July 2026
- KFF, "Medicare Advantage in 2026: Enrollment Update and Key Trends," 2026
- Healthcare Dive, "CMS recalculates Medicare Advantage stars after Clover lawsuit loss, but not a freebie for plans," 2026
- Fierce Healthcare, "On the heels of star rating win, Clover Health boosts outlook on strength of MA membership growth in Q2," August 2026
- Kiplinger, "Major Insurers Scale Back Medicare Advantage and Part D Plans for 2026," 2026
- Humana Inc., Form 8-K, July 2026